These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 27198690)

  • 1. So We Have Bioresorbable Scaffolds: Now What?
    King SB
    JACC Cardiovasc Interv; 2016 May; 9(10):1087-8. PubMed ID: 27198690
    [No Abstract]   [Full Text] [Related]  

  • 2. Bioresorbable scaffolds are here, please handle with care.
    Waksman R
    Cardiovasc Revasc Med; 2016 Sep; 17(6):353-4. PubMed ID: 27639107
    [No Abstract]   [Full Text] [Related]  

  • 3. Why Bioresorbable Vascular Scaffold Should Be Approved for Marketing in the United States.
    Waksman R
    Cardiovasc Revasc Med; 2015; 16(7):379-80. PubMed ID: 26573413
    [No Abstract]   [Full Text] [Related]  

  • 4. Advisory statement on clinical use of modified aortic endografts from the Society for Vascular Surgery®.
    White RA
    J Vasc Surg; 2013 Mar; 57(3):832-3. PubMed ID: 23446125
    [No Abstract]   [Full Text] [Related]  

  • 5. Bioresorbable metal scaffold for cardiovascular application: current knowledge and future perspectives.
    Kitabata H; Waksman R; Warnack B
    Cardiovasc Revasc Med; 2014 Mar; 15(2):109-16. PubMed ID: 24684760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioresorbable Scaffold-Based Controlled Drug Delivery for Restenosis.
    Tesfamariam B
    J Cardiovasc Transl Res; 2019 Jun; 12(3):193-203. PubMed ID: 30367355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Device regulation and surveillance in vascular care: Challenges and opportunities.
    Pyun AJ; Goodney PP; Eldrup-Jorgensen J; Wadzinski J; Secemsky EA; Cigarroa JE
    Catheter Cardiovasc Interv; 2024 Jul; 104(1):84-91. PubMed ID: 38639136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Manufacturer evaluations of endograft modifications.
    Waninger MS; Whirley RG; Smith LJ; Wolf BS
    J Vasc Surg; 2013 Mar; 57(3):826-8. PubMed ID: 23446123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A surgeon's perspective regarding the regulatory, compliance, and legal issues involved with physician-modified devices.
    Starnes BW
    J Vasc Surg; 2013 Mar; 57(3):829-31. PubMed ID: 23446124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility of endovascular repair of ascending aortic pathologies as part of an FDA-approved physician-sponsored investigational device exemption.
    Khoynezhad A; Donayre CE; Walot I; Koopmann MC; Kopchok GE; White RA
    J Vasc Surg; 2016 Jun; 63(6):1483-95. PubMed ID: 26926938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. For what were the instructions for use intended? The case of pararenal AAA repair.
    Upchurch GR; Tracci MC
    J Endovasc Ther; 2011 Apr; 18(2):197-8. PubMed ID: 21521059
    [No Abstract]   [Full Text] [Related]  

  • 12. Venous Stents: Current Status and Future Directions.
    Shamimi-Noori SM; Clark TWI
    Tech Vasc Interv Radiol; 2018 Jun; 21(2):113-116. PubMed ID: 29784119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of Investigational Device Exemptions regulations to endograft modification.
    Abel D; Farb A
    J Vasc Surg; 2013 Mar; 57(3):823-5. PubMed ID: 23446122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inclusion of comparative effectiveness data in high-risk cardiovascular device studies at the time of premarket approval.
    Chen CE; Dhruva SS; Redberg RF
    JAMA; 2012 Nov; 308(17):1740-2. PubMed ID: 23117769
    [No Abstract]   [Full Text] [Related]  

  • 15. FDA perspectives on postmarket surveillance of peripheral and aortic vascular devices.
    Malone M; Johnson CG
    Catheter Cardiovasc Interv; 2024 Jul; 104(1):170-171. PubMed ID: 38764289
    [No Abstract]   [Full Text] [Related]  

  • 16. Branched grafts for thoracoabdominal aneurysms: off-label use of FDA-approved devices.
    Kasirajan K
    J Endovasc Ther; 2011 Aug; 18(4):471-6. PubMed ID: 21861732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experiences with ascending aortic endografts using FDA IDE approved devices. What has been done, what lesions can be treated and what challenges remain.
    Muehle A; Chou D; Shah A; Khoynezhad A
    J Cardiovasc Surg (Torino); 2015 Feb; 56(1):11-8. PubMed ID: 25374411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overview of the 2011 food and drug administration's circulatory system devices panel of the medical devices advisory committee meeting on the Zilver® PTX® drug-eluting peripheral stent.
    Dvir D; Torguson R; Waksman R
    Cardiovasc Revasc Med; 2012; 13(5):281-5. PubMed ID: 22898055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Publication of Clinical Studies Supporting FDA Premarket Approval for High-Risk Cardiovascular Devices Between 2011 and 2013: A Cross-sectional Study.
    Phillips AT; Rathi VK; Ross JS
    JAMA Intern Med; 2016 Apr; 176(4):551-2. PubMed ID: 26902933
    [No Abstract]   [Full Text] [Related]  

  • 20. US Food and Drug Administration and Off-Label Use of Metal Expandable Biliary Stents within the Peripheral Vasculature-Update.
    Marrone AK; Gottschalk L; Chen AL
    J Vasc Interv Radiol; 2020 Apr; 31(4):622-628. PubMed ID: 32094048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.